13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Glutamate excitotoxicity might contribute to the pathophysiology of amyotrophic lateral sclerosis. In animal models, decreased excitatory aminoacid transporter 2 (EAAT2) overexpression delays disease onset and prolongs survival, and ceftriaxone increases EAAT2 activity. We aimed to assess the safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis in a combined phase 1, 2, and 3 clinical trial.

          Related collections

          Author and article information

          Journal
          Lancet Neurol
          The Lancet. Neurology
          1474-4465
          1474-4422
          Nov 2014
          : 13
          : 11
          Affiliations
          [1 ] Massachusetts General Hospital, Boston, MA, USA. Electronic address: mcudkowicz@partners.org.
          [2 ] Massachusetts General Hospital, Boston, MA, USA.
          [3 ] Carolinas Medical Centre, Charlotte, NC, USA.
          [4 ] National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
          [5 ] Tufts University School of Medicine, Boston, MA, USA.
          [6 ] Eliot Health System, Manchester, NH, USA.
          [7 ] Ohio State University, Columbus, OH, USA.
          [8 ] California Pacific Medical Center, San Francisco, CA, USA.
          [9 ] University of California-San Francisco, Fresno, CA, USA.
          [10 ] Johns Hopkins University, Baltimore, MD, USA.
          [11 ] Methodist Hospital, Houston, TX, USA.
          [12 ] Sunnybrook Health Science Centre, Toronto, ON, Canada.
          [13 ] State University of New York, Upstate Medical University, Syracuse, NY, USA.
          Article
          S1474-4422(14)70222-4 NIHMS635313
          10.1016/S1474-4422(14)70222-4
          25297012
          08c03bab-8dbb-43d0-9242-cb9188ad760a
          Copyright © 2014 Elsevier Ltd. All rights reserved.
          History

          Comments

          Comment on this article